Fubotv Inc vs Merck & Co., Inc. — how do they compare? Fubotv Inc trades at $9.28 (market cap $1.06B), while Merck & Co., Inc. trades at $132.77 (market cap $321.77B). The key difference: Merck & Co., Inc. is far larger — about 303.6× Fubotv Inc's market cap, and Merck & Co., Inc. pays a 2.61% dividend while Fubotv Inc pays none. Which is the better fit depends on your goals.
| FUBO | MRK | |
|---|---|---|
Market Cap | $1.06B | $321.77B |
Sector | Technology | Health |
52-Week High | $54.72 | $131.84 |
52-Week Low | $8.09 | $77.60 |
Enterprise Value | $1.23B | $368.53B |
Dividend Yield | — | 2.61% |
Signals from Pluang's Aura AI — not financial advice
FUBO trades at $9.46, up 1.07% today, with a bullish technical signal from moving averages and neutral oscillators. The company reported Q3 2026 revenue of $1.48 billion (Business Wire, 2026-08-05) and raised its full-year adjusted EBITDA target to $90–$100 million. Valuation ratios appear attractive with a P/S of 0.19 and P/B of 0.36, while recent earnings showed mixed results with two beats and one miss in the last four quarters.
The outlook is cautiously optimistic with analyst consensus pointing to significant upside to a $15.33 price target. Key opportunities include subscriber growth from live sports and advertising improvements, but risks persist from negative cash flows and high debt levels. Execution under new CEO Alisa Bowen and partnerships with Disney and NBCUniversal are critical for achieving profitability targets.
Merck & Co. (MRK) trades at $133.64, up 2.09% today, with a bullish technical signal from moving averages and strong institutional buying interest. The company reported solid earnings beats in recent quarters, with Q3 2026 EPS expected at $2.27. Revenue for 2025 reached $65.01B, and net income was $18.25B, though the P/E ratio of 104.34 suggests high valuation expectations. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline.
Outlook: MRK's growth is supported by strategic acquisitions and a dominant oncology franchise, but risks include high valuation multiples and competitive pressures. The consensus price target of $140.36 implies modest upside, with 68% of analysts rating it a Buy. Investors should monitor execution on the Terns integration and Q3 earnings results for catalysts.
Trailing returns across standard periods
Latest headlines on both assets
FuboTV Inc is a sports-first, live TV streaming company, offering subscribers access to tens of thousands of live sporting events annually as well as news and entertainment content. Its platform, fuboTV, allows customers to access content through streaming devices and on SmartTVs, mobile phones, tablets, and computers. The company offer subscribers a live TV streaming service with the option to purchase incremental features available for purchase that include additional content or enhanced functionality best suited to their preferences. The operating segments of the group are Streaming and Online wagering, of which a majority of revenue is derived from the Streaming segment. It has a business presence in the U.S. and other international countries.
Read more on FUBO →Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →